Sinus arrhythmia is a variation in the heart's sinus rhythm, usually caused by changes in a person's breathing cycle. It's a common finding, especially in children and young adults, and its ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...

Sinus arrhythmia refers to a changing sinus node rate with the respiratory cycle, on inspiration and expiration. This is quite common in young, healthy individuals and has no clinical significance.

While it’s most common in older adults, bradycardia can affect anyone and may occur alongside other conditions, including sinus arrhythmia. Continue reading to learn more about sinus bradycardia ...

Sinus rhythm (a.k.a. normal sinus rhythm) refers to the normal heart beat originating from the sinoatrial node. This is manifested as an upright P wave in lead II of the ECG. Sinus bradycardia ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Milestone Pharmaceuticals (MIST) announced the U.S. Food and Drug Administration, FDA, issued a Complete Response Letter, CRL, regarding its ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation, and although dronedarone is less effective it has a better safety profile. The choice of antiarrhythmic drug (or ...

Objective: To test whether ventilatory thresholds, measured during an exercise test, could be assessed using time varying analysis of respiratory sinus arrhythmia frequency (f RSA). Conclusions: ...